Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Operating expenses
Research and development	$ 2,768,997	$ 3,077,288	$ 7,044,575	$ 6,961,776
Research and development - related party (Note 7)	35,951	35,951	71,900	71,901
General and administrative	1,563,013	2,666,196	3,673,909	4,539,466
Total operating expenses	4,367,961	5,779,435	10,790,384	11,573,143
Other income (expense)
Interest income	6,555	12,422	16,709	56,899
Loss from equity investment in Aytu BioScience, Inc.	(690,834)		(1,043,353)
Total other income (expense)	(684,279)	12,422	(1,026,644)	56,899
Net loss from continuing operations	(5,052,240)	(5,767,013)	(11,817,028)	(11,516,244)
Loss from discontinued operations (Note 8)		(1,946,666)		(3,788,855)
Net loss	(5,052,240)	(7,713,679)	(11,817,028)	(15,305,099)
Net loss applicable to non-controlling interests		358,252		666,089
Net loss applicable to Ampio	$ (5,052,240)	$ (7,355,427)	$ (11,817,028)	$ (14,639,010)
Basic and diluted Ampio net loss per common share
From continuing operations	$ (0.10)	$ (0.11)	$ (0.23)	$ (0.22)
From discontinued operations and non-controlling interests		(0.03)		(0.06)
Net loss per share applicable to Ampio	$ (0.10)	$ (0.14)	$ (0.23)	$ (0.28)
Weighted average number of Ampio common shares outstanding	52,016,432	51,989,986	52,016,233	51,985,687